New York, October 15, 2009 – Although portions of proposed legislation from both the House Financial Services Committee and House Agriculture Committee to reform the over-the-counter (OTC) derivative market have been positively received by corporate end-users of derivatives, the ultimate outcome may mean the death or vast reduction in the number of customized hedges, according to Reval, a global derivative risk management and hedge accounting solutions provider.
“Two bills nearing votes in the House do not go far enough in introducing outright exemptions for corporate end-users of OTC derivatives and instead allow regulators to decide if corporations can be excluded from any margining or capital provisions,” says Jiro Okochi, CEO and Co-founder of Reval. “It is important that the end-user community continue to work with our members of Congress and regulators to improve the proposed legislation as we move forward.”
In their testimonies before Congress in recent months, representatives from several large companies, which use OTC derivatives to hedge against fluctuations in interest rates, foreign exchange rates and commodity prices, have asked to be exempt from having to trade on an exchange. The common view has been that end-users would decrease their use of hedging with OTC derivatives if required to post cash for margin and if standardized contracts did not allow enough flexibility to offset the specific business risk each company may have.
“I think there needs to be a bit of a wake-up call, as right now legislators feel like they are incorporating what corporate end-users need, but they are setting up market dynamics that may end up hurting the very swaps these corporate end-users want” Okochi warns. “So yes, corporate end-users may not have to post margin for customized swaps, but no one will be making markets in those products.”
According to Okochi, unless swap dealers have the same margin and capital posting exemption for hedges sold to corporate end-users, they will either increase prices to make it worthwhile to enter into customized swaps with corporations or may simply refrain from dealing with the hassle and costs of supporting this market.
“Some of the regulators have already indicated that they believe all OTC derivatives should be cleared or be on an exchange, so not specifically exempting corporate end-users in the legislation is risky,” Okochi says.”Even if the current commissions would give corporate end-users a pass today, what happens when a new commissioner with a different view is named?”
Reval has met with lawmakers to propose an outright exemption for corporate end-users and the derivatives they buy from swap dealers, providing they can prove that they are not speculating with derivatives and have a bona-fide hedge position.
“It is also unclear if the Senate will make matters better or worse for end users than the House bill does,” he says.
For more information about Reval and Jiro Okochi, please visit the news room at www.reval.com, and see www.savemyswaps.com.
For more information, visit www.reval.com or email email@example.com.
Note to editors: Trademarks and registered trademarks remain the property of their respective owners.